Puma Biotechnology, Inc.
PBYI
$8.83
$0.121.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 231.24M | 227.18M | 228.37M | 212.00M | 238.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 231.24M | 227.18M | 228.37M | 212.00M | 238.06M |
| Cost of Revenue | 58.20M | 58.03M | 58.16M | 48.95M | 65.88M |
| Gross Profit | 173.05M | 169.15M | 170.21M | 163.04M | 172.19M |
| SG&A Expenses | 71.17M | 71.67M | 70.85M | 69.09M | 69.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 200.81M | 197.69M | 191.07M | 178.44M | 192.00M |
| Operating Income | 30.44M | 29.49M | 37.30M | 33.56M | 46.06M |
| Income Before Tax | 31.17M | 29.09M | 35.78M | 30.91M | 42.28M |
| Income Tax Expenses | 4.45M | 4.70M | 4.67M | -6.07M | -6.17M |
| Earnings from Continuing Operations | 26.72 | 24.38 | 31.11 | 36.98 | 48.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.72M | 24.38M | 31.11M | 36.98M | 48.45M |
| EBIT | 30.44M | 29.49M | 37.30M | 33.56M | 46.06M |
| EBITDA | 40.12M | 39.41M | 47.44M | 43.28M | 55.94M |
| EPS Basic | 0.53 | 0.49 | 0.62 | 0.75 | 0.99 |
| Normalized Basic EPS | 0.39 | 0.36 | 0.45 | 0.39 | 0.54 |
| EPS Diluted | 0.51 | 0.47 | 0.61 | 0.74 | 0.98 |
| Normalized Diluted EPS | 0.38 | 0.36 | 0.44 | 0.39 | 0.53 |
| Average Basic Shares Outstanding | 202.46M | 201.22M | 199.97M | 198.73M | 197.40M |
| Average Diluted Shares Outstanding | 205.89M | 203.44M | 202.50M | 200.39M | 198.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |